Search
Clenbuterol
go.drugbank.com/drugs/DB01407ApprovedInvestigationalVet approvedA substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
Categories: Agents to Treat Airway DiseaseEplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalmultiple organs, although wild-type misfolded TTR has also been observed to contribute to the disease pathophysiology. … [A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Gemeprost
go.drugbank.com/drugs/DB08964ApprovedWithdrawnGemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. … It is available as vaginal suppositories and also used in combination with the antiprogestin and mifepristone for termination of 1st- and 2nd-trimester pregnancy [A19726].
Categories: Prostaglandins E, Prostaglandins E, SyntheticAvalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[L39205] The EMA approved the drug on June 24, 2022.[L42720] … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.
Synonyms: Adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase geneEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [A243759] The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in the destruction of these receptors
Levobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnto an anesthetic. … Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine.
Racemethionine
go.drugbank.com/drugs/DB13972ApprovedA preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.
Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% EPiracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnPiracetam has effects on the vascular system by reducing erythrocyte adhesion to the vascular endothelium, hindering vasospasms and facilitating microcirculation [A31532]. … It shares the same 2-oxo-pyrrolidone base structure with pyroglutamic acid and is a cyclic derivative of the neurotransmitter γ-aminobutyric acid (GABA).
Tridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is no longer available in the US market. … Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.